Vanguard Global Advisers
CSTL icon

Vanguard Global Advisers’s Castle Biosciences CSTL Stock Holding History

Vanguard Global Advisers’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$274K Hold
11,502
– – ﹤0.01% 2369
2026
Q1 		$282K Buy
+11,502
New +$377K ﹤0.01% 2273

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $112B AUM 36.28% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Global Advisers's CSTL Position: Q2 2026 in Review

Vanguard Global Advisers held its Castle Biosciences (CSTL) position steady in Q2 2026 at 11,502 shares worth $274K. The position accounts for ﹤0.01% of the portfolio, ranked #2369.

Vanguard Global Advisers first reported a position in CSTL in Q1 2026 and has held it in 2 quarters since. The position peaked at $282K in Q1 2026. 176 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Vanguard Global Advisers held 11,502 shares of Castle Biosciences worth $274K as of Q2 2026.
  • Vanguard Global Advisers left its Castle Biosciences share count unchanged in Q2 2026.
  • Castle Biosciences made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2369 holding.
  • Vanguard Global Advisers first reported a position in Castle Biosciences in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Castle Biosciences position peaked at $282K in Q1 2026.
  • 176 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.